224 related articles for article (PubMed ID: 24998878)
1. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
Nogawa H; Kawai T
Eur J Pharmacol; 2014 Oct; 741():336-9. PubMed ID: 24998878
[TBL] [Abstract][Full Text] [Related]
2. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
3. hERG: protein trafficking and potential for therapy and drug side effects.
Staudacher I; Schweizer PA; Katus HA; Thomas D
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):23-30. PubMed ID: 20047143
[TBL] [Abstract][Full Text] [Related]
4. High Glucose Represses hERG K+ Channel Expression through Trafficking Inhibition.
Shi YQ; Yan M; Liu LR; Zhang X; Wang X; Geng HZ; Zhao X; Li BX
Cell Physiol Biochem; 2015; 37(1):284-96. PubMed ID: 26303164
[TBL] [Abstract][Full Text] [Related]
5. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
6. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
7. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
8. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
[TBL] [Abstract][Full Text] [Related]
9. hERG channel trafficking: novel targets in drug-induced long QT syndrome.
Dennis A; Wang L; Wan X; Ficker E
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1060-3. PubMed ID: 17956279
[TBL] [Abstract][Full Text] [Related]
10. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.
Hancox JC; Mitcheson JS
Br J Pharmacol; 2006 Nov; 149(5):457-9. PubMed ID: 16967047
[TBL] [Abstract][Full Text] [Related]
11. [Progress in research on defective protein trafficking and functional restoration in HERG-associated long QT syndrome].
Fang P; Lian J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Feb; 33(1):101-4. PubMed ID: 26829745
[TBL] [Abstract][Full Text] [Related]
12. hERG potassium channels and cardiac arrhythmia.
Sanguinetti MC; Tristani-Firouzi M
Nature; 2006 Mar; 440(7083):463-9. PubMed ID: 16554806
[TBL] [Abstract][Full Text] [Related]
13. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
14. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes.
Guo J; Massaeli H; Li W; Xu J; Luo T; Shaw J; Kirshenbaum LA; Zhang S
J Pharmacol Exp Ther; 2007 Jun; 321(3):911-20. PubMed ID: 17377062
[TBL] [Abstract][Full Text] [Related]
15. The effects of a novel anti-arrhythmic drug, acehytisine hydrochloride, on the human ether-a-go-go related gene K channel and its trafficking.
Huang X; Yang Y; Zhu J; Dai Y; Pu J
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):145-54. PubMed ID: 19143746
[TBL] [Abstract][Full Text] [Related]
16. Progesterone impairs human ether-a-go-go-related gene (HERG) trafficking by disruption of intracellular cholesterol homeostasis.
Wu ZY; Yu DJ; Soong TW; Dawe GS; Bian JS
J Biol Chem; 2011 Jun; 286(25):22186-94. PubMed ID: 21525004
[TBL] [Abstract][Full Text] [Related]
17. The variant hERG/R148W associated with LQTS is a mutation that reduces current density on co-expression with the WT.
Mechakra A; Vincent Y; Chevalier P; Millat G; Ficker E; Jastrzebski M; Poulin H; Pouliot V; Chahine M; Christé G
Gene; 2014 Feb; 536(2):348-56. PubMed ID: 24334129
[TBL] [Abstract][Full Text] [Related]
18. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Han S; Zhang Y; Chen Q; Duan Y; Zheng T; Hu X; Zhang Z; Zhang L
Eur J Pharmacol; 2011 Jan; 650(1):138-44. PubMed ID: 20951697
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.
Stansfeld PJ; Sutcliffe MJ; Mitcheson JS
Expert Opin Drug Metab Toxicol; 2006 Feb; 2(1):81-94. PubMed ID: 16863470
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced hERG block and long QT syndrome.
Witchel HJ
Cardiovasc Ther; 2011 Aug; 29(4):251-9. PubMed ID: 20406244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
